The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
EUG-PEMETREXED (Eugia Pharma (Australia) Pty Ltd)
Product name
EUG-PEMETREXED
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
119 (175 working days)
Active ingredients
pemetrexed, pemetrexed disodium hemipentahydrate
Registration type
New generic medicine
Indication
Malignant Pleural Mesothelioma
EUG-PEMETREXED, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.
Non-Small Cell Lung Cancer
EUG-PEMETREXED in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
EUG-PEMETREXED as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.